Afuco™ Anti-Human HAMP ADCC Recombinant Antibody (LY2787106), ADCC Enhanced (CAT#: AFC-324CL)

Figure 1 Percent change in hemoglobin level from baseline to end of cycle 4 (week 12).

Values shown are for evaluable patients in study part B who received 10 mg/kg LY2787106 weekly (QW) without and with oral iron (cohorts B1 [n = 6] and B2 [n = 7], respectively). Only patients with a baseline and postbaseline result are included; for patients who did not reach week 12, their final assessment was used

Vadhan-Raj, S., Abonour, R., Goldman, J. W., Smith, D. A., Slapak, C. A., Ilaria, R. L., ... & Tuttle, J. L. (2017). A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia. Journal of hematology & oncology, 10(1), 73.

Figure 2 LY2787106 concentration-versus-time profile (a) and clearance-versus-dose scatter plot (b)

Vadhan-Raj, S., Abonour, R., Goldman, J. W., Smith, D. A., Slapak, C. A., Ilaria, R. L., ... & Tuttle, J. L. (2017). A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia. Journal of hematology & oncology, 10(1), 73.

Figure 3 Change in serum iron level (expressed as ratio relative to baseline) versus time course following (a) a single dose and (b) multiple weekly doses (after 5th dose).

Relative_Nominal_Time (h) is the protocol-scheduled time after last dose in hours presented on a log scale for greater clarity and better presentation of the earlier time point, where 168 h = 7 days = 1 week and 336 h = 14 days = 2 weeks. Data are displayed as mean ± SD

Vadhan-Raj, S., Abonour, R., Goldman, J. W., Smith, D. A., Slapak, C. A., Ilaria, R. L., ... & Tuttle, J. L. (2017). A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia. Journal of hematology & oncology, 10(1), 73.

Figure 4 Change in ferritin level (expressed as ratio relative to baseline) versus time course following (a) a single dose and (b) multiple weekly doses (after 5th dose).

Relative_Nominal_Time (hr) is the protocol-scheduled time after last dose in hours presented on a log scale for greater clarity and better presentation of the earlier time point, where 168 h = 7 days = 1 week and 336 h = 14 days = 2 weeks. Data are displayed as mean ± SD

Vadhan-Raj, S., Abonour, R., Goldman, J. W., Smith, D. A., Slapak, C. A., Ilaria, R. L., ... & Tuttle, J. L. (2017). A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia. Journal of hematology & oncology, 10(1), 73.

Figure 5 Transferrin saturation (percentage) concentration-versus-time profile following (a) a single dose and (b) multiple weekly doses (after 5th dose).

Relative_Nominal_Time (hr) is the protocol-scheduled time after last dose in hours presented on a log scale for greater clarity and better presentation of the earlier time point, where 168 h = 7 days = 1 week and 336 h = 14 days = 2 weeks. Data are displayed as mean ± SD

Vadhan-Raj, S., Abonour, R., Goldman, J. W., Smith, D. A., Slapak, C. A., Ilaria, R. L., ... & Tuttle, J. L. (2017). A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia. Journal of hematology & oncology, 10(1), 73.

Figure 6 Hepcidin (ng/mL) concentration-versus-time profile following (a) a single dose and (b) multiple weekly doses (after 5th dose).

Relative_Nominal_Time (hr) is the protocol-scheduled time after last dose in hours presented on a log scale for greater clarity and better presentation of the earlier time point, where 168 h = 7 days = 1 week and 336 h = 14 days = 2 weeks. Data are displayed as mean ± SD

Vadhan-Raj, S., Abonour, R., Goldman, J. W., Smith, D. A., Slapak, C. A., Ilaria, R. L., ... & Tuttle, J. L. (2017). A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia. Journal of hematology & oncology, 10(1), 73.